FDA: “The stroke risk is ‘significant’ but not as ‘striking’ as Myocarditis.”

“The sroke risk is ‘significant’ but not as ‘striking’ as Myocarditis.”

The FDA advisory committee met today and discussed its investigation into stroke risk in those 65+ after the Covid booster.